Article R5121-179 of the French Public Health Code
A decision by the Director General of the Agence nationale de sécurité du médicament et des produits de santé defines the principles of good pharmacovigilance practice. This decision also sets out the procedures for collecting, verifying and evaluating the information mentioned in Article R. 5121-151. It is published on the Agency’s website.